Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments
2021 Dec 01
Journal Article
Authors:
Sun, J.K.;
Josic, K.;
Melia, M.;
Glassman, A.R.;
Bailey, C.;
Chalam, K.V.;
Chew, E.Y.;
Cukras, C.;
Grover, S.;
Jaffe, G.J.;
Lee, R.;
Nielsen, J.S.;
Thompson, D.J.S.;
Wiley, H.E.;
Ferris, F.L.
Secondary:
Transl Vis Sci Technol
Volume:
10
Pagination:
34
Issue:
14
PMID:
34967834
URL:
https://pubmed.ncbi.nlm.nih.gov/34967834/
Keywords:
diabetes mellitus; Diabetic Retinopathy; Humans; macular edema; retina; Tomography, Optical Coherence
Abstract:
PURPOSE: Develop equations to convert Cirrus central subfield thickness (CST) to Spectralis CST equivalents and vice versa in eyes with diabetic macular edema (DME).METHODS: The DRCR Retina Network Protocol O data were split randomly to train (70% sample) and validate (30% sample) conversion equations. Data from an independent study (CADME) also validated the equations. Bland-Altman 95% limits of agreement between predicted and observed values evaluated the equations.RESULTS: Protocol O included 374 CST scan pairs from 187 eyes (107 participants). The CADME study included 150 scan pairs of 37 eyes (37 participants). Proposed conversion equations are Spectralis = 40.78 + 0.95 × Cirrus and Cirrus = 1.82 + 0.94 × Spectralis regardless of age, sex, or CST. Predicted values were within 10% of observed values in 101 (90%) of Spectralis and 99 (88%) of Cirrus scans in the validation data; and in 136 (91%) of the Spectralis and 148 (99%) of the Cirrus scans in the CADME data. Adjusting for within-eye correlations, 95% of conversions are estimated to be within 17% (95% confidence interval, 14%-21%) of CST on Spectralis and within 22% (95% confidence interval, 18%-28%) of CST on Cirrus.CONCLUSIONS: Conversion equations developed in this study allow the harmonization of CST measurements for eyes with DME using a mix of current Cirrus and Spectralis device images.TRANSLATIONAL RELEVANCE: The CSTs measured on Cirrus and Spectralis devices are not directly comparable owing to outer boundary segmentation differences. Converting CST values across spectral domain optical coherence tomography instruments should benefit both clinical research and standard care efforts.
